When it comes to risk assessment and diagnosis of prenatal aneuploidy and pre-eclampsia, early detection is essential. Clinically validated assays, combined with one of three scalable technology platforms and the industry leading informatics of our LifeCycle® risk calculation software, laboratories and clinics can achieve optimal screening performance while maximizing operational efficiency.
In the first trimester, our four CE-marked assays – PAPP-A, free hCGß, PlGF and AFP – provide effective screening for aneuploidy. Additionally the AFP marker can be used for screening for neural tube defects and the PlGF marker can be used for preeclampsia screening from a single sample. In the second trimester, our assay solutions enable you to run the cost-effective Double test or enhance your screening performance using the Triple test or 2T QUAD test.
With pre-eclampsia screening in the 1st trimester, women with increased risk for preterm pre-eclampsia can be identified to enable timely intervention. Later in pregnancy, PlGF based testing improves pre-eclampsia management for symptomatic women for improved prognosis, triage & diagnosis leading to better maternal & neonatal outcomes.
PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.